Repaglinide versus glyburide: a one-year comparison trial. (Q51562922)

7 April 2018

title

Repaglinide versus glyburide: a one-year comparison trial. (English)

1 reference

7 April 2018

author name string

Marbury T

1

1 reference

7 April 2018

Huang WC

2

1 reference

7 April 2018

Strange P

3

1 reference

7 April 2018

Lebovitz H

4

1 reference

7 April 2018

publication date

1 March 1999

1 reference

7 April 2018

Diabetes Research and Clinical Practice

published in

1 reference

7 April 2018

volume

43

1 reference

7 April 2018

page(s)

155-166

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

Undiagnosed NIDDM: clinical and public health issues.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Relation of glycemic control to diabetic microvascular complications in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Comparative tolerability profiles of oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2899%2900002-9

7 January 2021

10.1016/S0168-8227(99)00002-9

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

10369424

1 reference

7 April 2018